EmbeddingGemma 2: an open, lightweight multimodal embedding model
deepmind.google·6d ago
AI Engineering
Hacker News·21d ago·5 min read
'Epigenetic' editing banishes hepatitis B virus
TL;DR
Researchers have developed an epigenetic therapy that effectively silences the hepatitis B virus (HBV) by modifying its genome, showing promising results in preclinical trials. This approach could lead to a significant advancement in treating chronic hepatitis B, which affects over 250 million people globally.
✦ Why It Matters
Consider supporting or following developments in epigenetic therapies for hepatitis B to stay informed on potential breakthroughs.
Key Takeaways
- Explore the implications of epigenetic editing in viral therapies.
- Stay informed about clinical trial results for CRMA-1001.
- Consider the safety profile of new therapies compared to traditional methods.
- Engage with ongoing research in gene therapy and its applications.
How It Works
CRMA-1001 employs a modified CRISPR Cas9 enzyme that lacks cutting ability, instead using RNA strands to guide it to specific targets in the HBV genome. The therapy encapsulates these components in lipid nanoparticles, allowing it to tag both free-ranging and integrated HBV DNA with methyl groups, effectively silencing the virus.